223 related articles for article (PubMed ID: 38407050)
1. Beyond CSF and Neuroimaging Assessment: Evaluating Plasma miR-145-5p as a Potential Biomarker for Mild Cognitive Impairment and Alzheimer's Disease.
Wen Q; Wittens MMJ; Engelborghs S; van Herwijnen MHM; Tsamou M; Roggen E; Smeets B; Krauskopf J; Briedé JJ
ACS Chem Neurosci; 2024 Mar; 15(5):1042-1054. PubMed ID: 38407050
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of endogenous control miRNAs in plasma samples for normalization of qPCR data for Alzheimer's disease.
Dakterzada F; Targa A; Benítez ID; Romero-ElKhayat L; de Gonzalo-Calvo D; Torres G; Moncusí-Moix A; Huerto R; Sánchez-de-la-Torre M; Barbé F; Piñol-Ripoll G
Alzheimers Res Ther; 2020 Dec; 12(1):163. PubMed ID: 33278902
[TBL] [Abstract][Full Text] [Related]
3. Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer's disease.
Jia L; Zhu M; Yang J; Pang Y; Wang Q; Li Y; Li T; Li F; Wang Q; Li Y; Wei Y
BMC Med; 2021 Nov; 19(1):264. PubMed ID: 34775974
[TBL] [Abstract][Full Text] [Related]
4. Performance of Validated MicroRNA Biomarkers for Alzheimer's Disease in Mild Cognitive Impairment.
Sandau US; Wiedrick JT; Smith SJ; McFarland TJ; Lusardi TA; Lind B; Harrington CA; Lapidus JA; Galasko DR; Quinn JF; Saugstad JA
J Alzheimers Dis; 2020; 78(1):245-263. PubMed ID: 32955460
[TBL] [Abstract][Full Text] [Related]
5. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
6. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
7. Profile of Pathogenic Proteins and MicroRNAs in Plasma-derived Extracellular Vesicles in Alzheimer's Disease: A Pilot Study.
Li F; Xie XY; Sui XF; Wang P; Chen Z; Zhang JB
Neuroscience; 2020 Apr; 432():240-246. PubMed ID: 32135232
[TBL] [Abstract][Full Text] [Related]
8. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative.
Zettergren A; Lord J; Ashton NJ; Benedet AL; Karikari TK; Lantero Rodriguez J; ; Snellman A; Suárez-Calvet M; Proitsi P; Zetterberg H; Blennow K
Alzheimers Res Ther; 2021 Jan; 13(1):17. PubMed ID: 33419453
[TBL] [Abstract][Full Text] [Related]
9. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
[TBL] [Abstract][Full Text] [Related]
10. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
11. Sex differences in Alzheimer's disease: plasma MMP-9 and markers of disease severity.
Tsiknia AA; Sundermann EE; Reas ET; Edland SD; Brewer JB; Galasko D; Banks SJ;
Alzheimers Res Ther; 2022 Nov; 14(1):160. PubMed ID: 36324151
[TBL] [Abstract][Full Text] [Related]
12. MiRNA -483-5p as a Potential Noninvasive Biomarker for Early Detection of Alzheimer's Disease.
Sabry R; El Sharkawy RE; Gad NM
Egypt J Immunol; 2020 Jun; 27(2):59-72. PubMed ID: 33548978
[TBL] [Abstract][Full Text] [Related]
13. Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.
Babić Leko M; Borovečki F; Dejanović N; Hof PR; Šimić G
J Alzheimers Dis; 2016; 50(3):765-78. PubMed ID: 26836160
[TBL] [Abstract][Full Text] [Related]
14. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
[TBL] [Abstract][Full Text] [Related]
15. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
[TBL] [Abstract][Full Text] [Related]
16. The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Li Z; Fan Z; Zhang Q
J Alzheimers Dis; 2024; 98(1):13-32. PubMed ID: 38339929
[TBL] [Abstract][Full Text] [Related]
17. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
18. Upregulated Blood miR-150-5p in Alzheimer's Disease Dementia Is Associated with Cognition, Cerebrospinal Fluid Amyloid-β, and Cerebral Atrophy.
Chia SY; Vipin A; Ng KP; Tu H; Bommakanti A; Wang BZ; Tan YJ; Zailan FZ; Ng ASL; Ling SC; Okamura K; Tan EK; Kandiah N; Zeng L
J Alzheimers Dis; 2022; 88(4):1567-1584. PubMed ID: 35811521
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
Karikari TK; Benedet AL; Ashton NJ; Lantero Rodriguez J; Snellman A; Suárez-Calvet M; Saha-Chaudhuri P; Lussier F; Kvartsberg H; Rial AM; Pascoal TA; Andreasson U; Schöll M; Weiner MW; Rosa-Neto P; Trojanowski JQ; Shaw LM; Blennow K; Zetterberg H;
Mol Psychiatry; 2021 Feb; 26(2):429-442. PubMed ID: 33106600
[TBL] [Abstract][Full Text] [Related]
20. An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/Aβ1-42 Ratio in ApoE4-Negative Mild Cognitive Impairment Patients.
Sun Y; Bresell A; Rantalainen M; Höglund K; Lebouvier T; Salter H;
J Alzheimers Dis; 2015; 45(4):1061-76. PubMed ID: 25720397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
